BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, Mikami A, Roberts TM. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA. 2006;103:16296-16300. [PMID: 17060635 DOI: 10.1073/pnas.0607899103] [Cited by in Crossref: 156] [Cited by in F6Publishing: 155] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Stephens L, Hawkins P. Signalling via class IA PI3Ks. Adv Enzyme Regul 2011;51:27-36. [PMID: 21035483 DOI: 10.1016/j.advenzreg.2010.09.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
2 Ellis H, Ma CX. PI3K Inhibitors in Breast Cancer Therapy. Curr Oncol Rep 2019;21:110. [PMID: 31828441 DOI: 10.1007/s11912-019-0846-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
3 Yun S, Jung KH, Lee H, Son MK, Seo J, Yan HH, Park BH, Hong S, Hong S. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Cancer Letters 2013;331:250-61. [DOI: 10.1016/j.canlet.2013.01.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
4 Geering B, Cutillas P, Vanhaesebroeck B. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits? Biochemical Society Transactions 2007;35:199-203. [DOI: 10.1042/bst0350199] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
5 Maira SM, Finan P, Garcia-Echeverria C. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr Top Microbiol Immunol 2010;347:209-39. [PMID: 20582534 DOI: 10.1007/82_2010_60] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
6 Lucas CL, Zhang Y, Venida A, Wang Y, Hughes J, McElwee J, Butrick M, Matthews H, Price S, Biancalana M, Wang X, Richards M, Pozos T, Barlan I, Ozen A, Rao VK, Su HC, Lenardo MJ. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med 2014;211:2537-47. [PMID: 25488983 DOI: 10.1084/jem.20141759] [Cited by in Crossref: 161] [Cited by in F6Publishing: 146] [Article Influence: 20.1] [Reference Citation Analysis]
7 Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2013;39:313-20. [PMID: 23218708 DOI: 10.1016/j.ctrv.2012.11.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
8 Ilić N, Roberts TM. Comparing the roles of the p110α and p110β isoforms of PI3K in signaling and cancer. Curr Top Microbiol Immunol 2010;347:55-77. [PMID: 20517719 DOI: 10.1007/82_2010_63] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
9 Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009;21:199-208. [PMID: 19200708 DOI: 10.1016/j.ceb.2008.12.007] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
10 Utermark T, Schaffhausen BS, Roberts TM, Zhao JJ. The p110alpha isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation. J Virol 2007;81:7069-76. [PMID: 17442716 DOI: 10.1128/JVI.00115-07] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
11 Mayer IA, Dent R, Tan T, Savas P, Loi S. Novel Targeted Agents and Immunotherapy in Breast Cancer. Am Soc Clin Oncol Educ Book 2017;37:65-75. [PMID: 28561712 DOI: 10.1200/EDBK_175631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
12 Aleskandarany MA, Sonbul S, Surridge R, Mukherjee A, Caldas C, Diez-Rodriguez M, Ashankyty I, Albrahim KI, Elmouna AM, Aneja R, Martin SG, Ellis IO, Green AR, Rakha EA. Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. Br J Cancer 2017;117:1176-84. [PMID: 28829761 DOI: 10.1038/bjc.2017.261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
13 Murillo MM, Rana S, Spencer-Dene B, Nye E, Stamp G, Downward J. Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer. Cell Rep 2018;25:3545-3553.e2. [PMID: 30590030 DOI: 10.1016/j.celrep.2018.12.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
14 Berghausen EM, Janssen W, Vantler M, Gnatzy-Feik LL, Krause M, Behringer A, Joseph C, Zierden M, Freyhaus HT, Klinke A, Baldus S, Alcazar MA, Savai R, Pullamsetti SS, Wong DW, Boor P, Zhao JJ, Schermuly RT, Rosenkranz S. Disrupted PI3K subunit p110α signaling protects against pulmonary hypertension and reverses established disease in rodents. J Clin Invest 2021;131:e136939. [PMID: 34596056 DOI: 10.1172/JCI136939] [Reference Citation Analysis]
15 Smith GC, Ong WK, Costa JL, Watson M, Cornish J, Grey A, Gamble GD, Dickinson M, Leung S, Rewcastle GW, Han W, Shepherd PR. Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength. FEBS J 2013;280:5337-49. [PMID: 23837532 DOI: 10.1111/febs.12428] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
16 Garcia-Galiano D, Borges BC, Donato J Jr, Allen SJ, Bellefontaine N, Wang M, Zhao JJ, Kozloff KM, Hill JW, Elias CF. PI3Kα inactivation in leptin receptor cells increases leptin sensitivity but disrupts growth and reproduction. JCI Insight 2017;2:96728. [PMID: 29212950 DOI: 10.1172/jci.insight.96728] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
17 Madsen L, Kristiansen K. The importance of dietary modulation of cAMP and insulin signaling in adipose tissue and the development of obesity. Ann N Y Acad Sci 2010;1190:1-14. [PMID: 20388132 DOI: 10.1111/j.1749-6632.2009.05262.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
18 Saito K, He Y, Yang Y, Zhu L, Wang C, Xu P, Hinton AO, Yan X, Zhao J, Fukuda M, Tong Q, Clegg DJ, Xu Y. PI3K in the ventromedial hypothalamic nucleus mediates estrogenic actions on energy expenditure in female mice. Sci Rep 2016;6:23459. [PMID: 26988598 DOI: 10.1038/srep23459] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
19 Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3 CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res. 2017;23:6823-6832. [PMID: 28874413 DOI: 10.1158/1078-0432.ccr-17-1260] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 8.6] [Reference Citation Analysis]
20 Ye Y, Tang X, Sun Z, Chen S. Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion. Oncotarget 2016;7:17854-69. [PMID: 26895380 DOI: 10.18632/oncotarget.7439] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
21 Nunnery SE, Mayer IA. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol 2019;30 Suppl 10:x21-6. [PMID: 31928691 DOI: 10.1093/annonc/mdz440] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
22 Cizmecioglu O, Ni J, Xie S, Zhao JJ, Roberts TM. Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss. Elife 2016;5:e17635. [PMID: 27700986 DOI: 10.7554/eLife.17635] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
23 Grey A, Chaussade C, Empson V, Lin J, Watson M, O’sullivan S, Rewcastle G, Naot D, Cornish J, Shepherd P. Evidence for a role for the p110-α isoform of PI3K in skeletal function. Biochemical and Biophysical Research Communications 2010;391:564-9. [DOI: 10.1016/j.bbrc.2009.11.099] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
24 Ortega-molina A, Efeyan A, Lopez-guadamillas E, Muñoz-martin M, Gómez-lópez G, Cañamero M, Mulero F, Pastor J, Martinez S, Romanos E, Mar gonzalez-barroso M, Rial E, Valverde A, Bischoff J, Serrano M. Pten Positively Regulates Brown Adipose Function, Energy Expenditure, and Longevity. Cell Metabolism 2012;15:382-94. [DOI: 10.1016/j.cmet.2012.02.001] [Cited by in Crossref: 241] [Cited by in F6Publishing: 214] [Article Influence: 24.1] [Reference Citation Analysis]
25 Chang H, Cai Z, Roberts TM. The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. Biomolecules 2019;9:E713. [PMID: 31703360 DOI: 10.3390/biom9110713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, Fernandez de Mattos S, Wymann MP, Brosens JJ, Schulze A, Lam EW. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 2008;28:5886-98. [PMID: 18644865 DOI: 10.1128/MCB.01265-07] [Cited by in Crossref: 102] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
27 Guo W, You X, Wang X, Wang L, Chen Y. A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells. Cancer Lett 2017;405:1-9. [PMID: 28743532 DOI: 10.1016/j.canlet.2017.07.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
28 Fluck MM, Schaffhausen BS. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev 2009;73:542-63, Table of Contents. [PMID: 19721090 DOI: 10.1128/MMBR.00009-09] [Cited by in Crossref: 109] [Cited by in F6Publishing: 83] [Article Influence: 8.4] [Reference Citation Analysis]
29 Xu T, Xiao D, Zhang X. ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck in vitro and in vivo.. Oncol Lett 2013;5:1921-6. [PMID: 23833667 DOI: 10.3892/ol.2013.1298] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
30 Porporato PE, Filigheddu N, Reano S, Ferrara M, Angelino E, Gnocchi VF, Prodam F, Ronchi G, Fagoonee S, Fornaro M, Chianale F, Baldanzi G, Surico N, Sinigaglia F, Perroteau I, Smith RG, Sun Y, Geuna S, Graziani A. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest 2013;123:611-22. [PMID: 23281394 DOI: 10.1172/JCI39920] [Cited by in Crossref: 24] [Cited by in F6Publishing: 64] [Article Influence: 2.7] [Reference Citation Analysis]
31 Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J. RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. J Clin Invest 2014;124:3601-11. [PMID: 25003191 DOI: 10.1172/JCI74134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
32 Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012;10:161. [PMID: 23232172 DOI: 10.1186/1741-7015-10-161] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
33 Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene 2016;35:3607-12. [PMID: 26500061 DOI: 10.1038/onc.2015.406] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
34 Chang HJ, Shin HS, Kim TH, Yoo JY, Teasley HE, Zhao JJ, Ha UH, Jeong JW. Pik3ca is required for mouse uterine gland development and pregnancy. PLoS One 2018;13:e0191433. [PMID: 29346447 DOI: 10.1371/journal.pone.0191433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
35 Zhang K, Liu X, Han M, Liu Y, Wang X, Yu H, Liu J, Zhang Q. Functional differentiation of three phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) in response to Vibrio anguillarum infection in turbot (Scophthalmus maximus). Fish Shellfish Immunol 2019;92:450-9. [PMID: 31207302 DOI: 10.1016/j.fsi.2019.06.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Tan J, Lee PL, Li Z, Jiang X, Lim YC, Hooi SC, Yu Q. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell. 2010;18:459-471. [PMID: 21075311 DOI: 10.1016/j.ccr.2010.10.021] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 5.8] [Reference Citation Analysis]
37 Tsolakos N, Durrant TN, Chessa T, Suire SM, Oxley D, Kulkarni S, Downward J, Perisic O, Williams RL, Stephens L, Hawkins PT. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. Proc Natl Acad Sci U S A 2018;115:12176-81. [PMID: 30442661 DOI: 10.1073/pnas.1803446115] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
38 Paz-Ares L, Blanco-Aparicio C, García-Carbonero R, Carnero A. Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol 2009;11:572-9. [PMID: 19775996 DOI: 10.1007/s12094-009-0407-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
39 Yun SM, Kim YS, Hur DY. LMP1 and 2A Induce the Expression of Nrf2 Through Akt Signaling Pathway in Epstein-Barr Virus-Transformed B Cells. Transl Oncol 2019;12:775-83. [PMID: 30909091 DOI: 10.1016/j.tranon.2019.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
40 Al Dow M, Silveira MAD, Poliquin A, Tribouillard L, Fournier É, Trébaol E, Secco B, Villot R, Tremblay F, Bilodeau S, Laplante M. Control of adipogenic commitment by a STAT3-VSTM2A axis. Am J Physiol Endocrinol Metab 2021;320:E259-69. [PMID: 33196296 DOI: 10.1152/ajpendo.00314.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Spangle JM, Von T, Pavlick DC, Khotimsky A, Zhao JJ, Roberts TM. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition. Proc Natl Acad Sci U S A 2020;117:24427-33. [PMID: 32929011 DOI: 10.1073/pnas.2000060117] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Zhang Z, Liu J, Wang Y, Tan X, Zhao W, Xing X, Qiu Y, Wang R, Jin M, Fan G, Zhang P, Zhong Y, Kong D. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells. FASEB J 2018;32:5967-75. [PMID: 29792732 DOI: 10.1096/fj.201800183R] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
43 Wang Q, Von T, Bronson R, Ruan M, Mu W, Huang A, Maira SM, Zhao JJ. Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. Genes Dev 2013;27:1568-80. [PMID: 23873941 DOI: 10.1101/gad.216069.113] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
44 Tan DSW, Adjei AA. Toward High-Precision Genomic Biomarkers: The Importance of Context. J Thorac Oncol 2015;10:1237-9. [PMID: 26291006 DOI: 10.1097/JTO.0000000000000633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008;454:776-779. [PMID: 18594509 DOI: 10.1038/nature07091] [Cited by in Crossref: 520] [Cited by in F6Publishing: 488] [Article Influence: 37.1] [Reference Citation Analysis]
46 Utermark T, Schmit F, Lee SH, Gao X, Schaffhausen BS, Roberts TM. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type. J Virol 2014;88:10673-9. [PMID: 24991009 DOI: 10.1128/JVI.01409-14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
47 Burke JE, Williams RL. Synergy in activating class I PI3Ks. Trends Biochem Sci 2015;40:88-100. [PMID: 25573003 DOI: 10.1016/j.tibs.2014.12.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 14.4] [Reference Citation Analysis]
48 Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One 2009;4:e4715. [PMID: 19262748 DOI: 10.1371/journal.pone.0004715] [Cited by in Crossref: 91] [Cited by in F6Publishing: 91] [Article Influence: 7.0] [Reference Citation Analysis]
49 Engelbrecht AM, Toit-Kohn JL, Ellis B, Thomas M, Nell T, Smith R. Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model. Apoptosis 2008;13:1368-77. [PMID: 18785011 DOI: 10.1007/s10495-008-0260-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
50 Mahajan K, Mahajan NP. Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J Cell Physiol. 2010;224:327-333. [PMID: 20432460 DOI: 10.1002/jcp.22162] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
51 Ariyama J, Suyama M, Ogawa K, Ikari T, Nagaiwa J, Fujii D, Tsuchida A. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol. 1990;7:37-47. [PMID: 1964473 DOI: 10.1038/nrd2926] [Cited by in Crossref: 1691] [Cited by in F6Publishing: 1605] [Article Influence: 54.5] [Reference Citation Analysis]
52 Pérez-García V, Redondo-Muñoz J, Kumar A, Carrera AC. Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity. Mol Cell Biol 2014;34:3359-73. [PMID: 24958106 DOI: 10.1128/MCB.00167-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res 2009;15:3029-36. [PMID: 19383818 DOI: 10.1158/1078-0432.CCR-08-2768] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
54 Chaudhari A, Ejeskär K, Wettergren Y, Kahn CR, Rotter Sopasakis V. Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity. F1000Res 2017;6:1600. [PMID: 29983910 DOI: 10.12688/f1000research.12418.2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Kim JE, Shepherd PR, Chaussade C. Investigating the role of class-IA PI 3-kinase isoforms in adipocyte differentiation. Biochemical and Biophysical Research Communications 2009;379:830-4. [DOI: 10.1016/j.bbrc.2008.12.089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
56 Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012;26:1573-1586. [PMID: 22802530 DOI: 10.1101/gad.191973.112] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 9.3] [Reference Citation Analysis]
57 Xu Y, Hill JW, Fukuda M, Gautron L, Sohn JW, Kim KW, Lee CE, Choi MJ, Lauzon DA, Dhillon H, Lowell BB, Zigman JM, Zhao JJ, Elmquist JK. PI3K signaling in the ventromedial hypothalamic nucleus is required for normal energy homeostasis. Cell Metab 2010;12:88-95. [PMID: 20620998 DOI: 10.1016/j.cmet.2010.05.002] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
58 Simond AM, Rao T, Zuo D, Zhao JJ, Muller WJ. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor. Oncogene 2017;36:6059-66. [PMID: 28783168 DOI: 10.1038/onc.2017.264] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
59 Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013;31:675-704. [PMID: 23330955 DOI: 10.1146/annurev-immunol-032712-095946] [Cited by in Crossref: 245] [Cited by in F6Publishing: 241] [Article Influence: 27.2] [Reference Citation Analysis]
60 Nunnery SE, Mayer IA. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs 2020;80:1685-97. [PMID: 32894420 DOI: 10.1007/s40265-020-01394-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
61 Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell 2015;27:97-108. [PMID: 25544637 DOI: 10.1016/j.ccell.2014.11.007] [Cited by in Crossref: 132] [Cited by in F6Publishing: 111] [Article Influence: 16.5] [Reference Citation Analysis]
62 Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. AKT-independent PI3-K signaling in cancer - emerging role for SGK3. Cancer Manag Res 2013;5:281-92. [PMID: 24009430 DOI: 10.2147/CMAR.S35178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 39] [Article Influence: 0.4] [Reference Citation Analysis]
63 Foukas LC, Bilanges B, Bettedi L, Pearce W, Ali K, Sancho S, Withers DJ, Vanhaesebroeck B. Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol Med 2013;5:563-71. [PMID: 23483710 DOI: 10.1002/emmm.201201953] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
64 Vogt PK, Kang S, Elsliger MA, Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci. 2007;32:342-349. [PMID: 17561399 DOI: 10.1016/j.tibs.2007.05.005] [Cited by in Crossref: 109] [Cited by in F6Publishing: 108] [Article Influence: 7.3] [Reference Citation Analysis]
65 Wang G, Zhu H, Situ C, Han L, Yu Y, Cheung TH, Liu K, Wu Z. p110α of PI3K is necessary and sufficient for quiescence exit in adult muscle satellite cells. EMBO J 2018;37:e98239. [PMID: 29581096 DOI: 10.15252/embj.201798239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
66 Castellano E, Downward J. RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer 2011;2:261-74. [PMID: 21779497 DOI: 10.1177/1947601911408079] [Cited by in Crossref: 412] [Cited by in F6Publishing: 398] [Article Influence: 37.5] [Reference Citation Analysis]
67 Hill JW, Xu Y, Preitner F, Fukuda M, Cho YR, Luo J, Balthasar N, Coppari R, Cantley LC, Kahn BB, Zhao JJ, Elmquist JK. Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis. Endocrinology 2009;150:4874-82. [PMID: 19819947 DOI: 10.1210/en.2009-0454] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
68 Juvin V, Malek M, Anderson KE, Dion C, Chessa T, Lecureuil C, Ferguson GJ, Cosulich S, Hawkins PT, Stephens LR. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines. PLoS One 2013;8:e75045. [PMID: 24124465 DOI: 10.1371/journal.pone.0075045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
69 Ramadani F, Bolland DJ, Garcon F, Emery JL, Vanhaesebroeck B, Corcoran AE, Okkenhaug K. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal 2010;3:ra60. [PMID: 20699475 DOI: 10.1126/scisignal.2001104] [Cited by in Crossref: 135] [Cited by in F6Publishing: 136] [Article Influence: 11.3] [Reference Citation Analysis]
70 Durrant TN, Hers I. PI3K inhibitors in thrombosis and cardiovascular disease. Clin Transl Med 2020;9:8. [PMID: 32002690 DOI: 10.1186/s40169-020-0261-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
71 Martin SK, Fitter S, Bong LF, Drew JJ, Gronthos S, Shepherd PR, Zannettino AC. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res 2010;25:2126-37. [DOI: 10.1002/jbmr.114] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
72 Cheng CK, Fan QW, Weiss WA. PI3K signaling in glioma--animal models and therapeutic challenges. Brain Pathol 2009;19:112-20. [PMID: 19076776 DOI: 10.1111/j.1750-3639.2008.00233.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 5.6] [Reference Citation Analysis]
73 Sadasivan C, Zhabyeyev P, Labib D, White JA, Paterson DI, Oudit GY. Cardiovascular toxicity of PI3Kα inhibitors. Clin Sci (Lond) 2020;134:2595-622. [PMID: 33063821 DOI: 10.1042/CS20200302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
74 Garcia-Galiano D, Borges BC, Allen SJ, Elias CF. PI3K signalling in leptin receptor cells: Role in growth and reproduction. J Neuroendocrinol 2019;31:e12685. [PMID: 30618188 DOI: 10.1111/jne.12685] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
75 Huang WS, Wang TB, He Y, Chen YJ, Zhong SL, Tan M. Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol 2012; 18(26): 3458-3464 [PMID: 22807617 DOI: 10.3748/wjg.v18.i26.3458] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
76 Mellor P, Furber L, Nyarko J, Anderson D. Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking. Biochemical Journal 2012;441:23-37. [DOI: 10.1042/bj20111164] [Cited by in Crossref: 63] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
77 Kandoussi I, Benherrif O, Lakhlili W, Taoufik J, Ibrahimi A. Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers. Contemp Oncol (Pozn) 2020;24:5-12. [PMID: 32514232 DOI: 10.5114/wo.2020.93334] [Reference Citation Analysis]
78 Williams KW, Sohn JW, Donato J, Lee CE, Zhao JJ, Elmquist JK, Elias CF. The acute effects of leptin require PI3K signaling in the hypothalamic ventral premammillary nucleus. J Neurosci. 2011;31:13147-13156. [PMID: 21917798 DOI: 10.1523/JNEUROSCI.2602-11.2011] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
79 Zhu L, Xu P, Cao X, Yang Y, Hinton AO Jr, Xia Y, Saito K, Yan X, Zou F, Ding H, Wang C, Yan C, Saha P, Khan SA, Zhao J, Fukuda M, Tong Q, Clegg DJ, Chan L, Xu Y. The ERα-PI3K Cascade in Proopiomelanocortin Progenitor Neurons Regulates Feeding and Glucose Balance in Female Mice. Endocrinology 2015;156:4474-91. [PMID: 26375425 DOI: 10.1210/en.2015-1660] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
80 Donato J Jr, Frazão R, Elias CF. The PI3K signaling pathway mediates the biological effects of leptin. Arq Bras Endocrinol Metabol 2010;54:591-602. [PMID: 21085763 DOI: 10.1590/s0004-27302010000700002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
81 Zhang Z, Zhang L, Wang B, Wei R, Wang Y, Wan J, Zhang C, Zhao L, Zhu X, Zhang Y, Chu C, Guo Q, Yin X, Li X. MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB. Cancer Lett 2020;469:54-67. [PMID: 31629932 DOI: 10.1016/j.canlet.2019.10.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
82 Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A 2007;104:7809-14. [PMID: 17470792 DOI: 10.1073/pnas.0700373104] [Cited by in Crossref: 159] [Cited by in F6Publishing: 150] [Article Influence: 10.6] [Reference Citation Analysis]
83 Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ. A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nat Commun 2015;6:8501. [PMID: 26442967 DOI: 10.1038/ncomms9501] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
84 Du L, Shen J, Weems A, Lu SL. Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. J Oncol 2012;2012:450179. [PMID: 22666248 DOI: 10.1155/2012/450179] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
85 Cao S, Chen C, Xue J, Huang Y, Yang X, Ling K. Silencing of type Iγ phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion. Oncol Rep 2017;38:253-62. [PMID: 28560454 DOI: 10.3892/or.2017.5670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
86 Campa CC, Ciraolo E, Ghigo A, Germena G, Hirsch E. Crossroads of PI3K and Rac pathways. Small GTPases 2015;6:71-80. [PMID: 25942647 DOI: 10.4161/21541248.2014.989789] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
87 Makino A, Arai T, Hirata M, Ono M, Ohmomo Y, Saji H. Development of novel PET probes targeting phosphatidylinositol 3-kinase (PI3K) in tumors. Nucl Med Biol 2016;43:101-7. [PMID: 26602328 DOI: 10.1016/j.nucmedbio.2015.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
88 Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncology 2011;7:1149-67. [DOI: 10.2217/fon.11.95] [Cited by in Crossref: 118] [Cited by in F6Publishing: 125] [Article Influence: 10.7] [Reference Citation Analysis]
89 Maira SM, Furet P, Stauffer F. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. Future Med Chem 2009;1:137-55. [PMID: 21426073 DOI: 10.4155/fmc.09.5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
90 Méndez-Pertuz M, Martínez P, Blanco-Aparicio C, Gómez-Casero E, Belen García A, Martínez-Torrecuadrada J, Palafox M, Cortés J, Serra V, Pastor J, Blasco MA. Modulation of telomere protection by the PI3K/AKT pathway. Nat Commun 2017;8:1278. [PMID: 29097657 DOI: 10.1038/s41467-017-01329-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
91 Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2011;117:361-371. [PMID: 20839315 DOI: 10.1002/cncr.25555] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
92 Burke JE. Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease. Molecular Cell 2018;71:653-73. [DOI: 10.1016/j.molcel.2018.08.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 19.3] [Reference Citation Analysis]
93 Astanehe A, Finkbeiner MR, Hojabrpour P, To K, Fotovati A, Shadeo A, Stratford AL, Lam WL, Berquin IM, Duronio V, Dunn SE. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 2009;28:2406-18. [PMID: 19430491 DOI: 10.1038/onc.2009.81] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
94 Jiang B, Liu L. Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis. Elsevier; 2009. pp. 19-65. [DOI: 10.1016/s0065-230x(09)02002-8] [Cited by in Crossref: 308] [Cited by in F6Publishing: 199] [Article Influence: 23.7] [Reference Citation Analysis]
95 Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends in Biochemical Sciences 2009;34:115-27. [DOI: 10.1016/j.tibs.2009.01.003] [Cited by in Crossref: 156] [Cited by in F6Publishing: 149] [Article Influence: 12.0] [Reference Citation Analysis]
96 Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94 Suppl 2:S107-S121. [PMID: 25814077 DOI: 10.1007/s00277-015-2325-z] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 13.6] [Reference Citation Analysis]
97 Gurska LM, Ames K, Gritsman K. Signaling Pathways in Leukemic Stem Cells. Adv Exp Med Biol 2019;1143:1-39. [PMID: 31338813 DOI: 10.1007/978-981-13-7342-8_1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
98 Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515-524. [PMID: 27896521 DOI: 10.1007/s10555-016-9637-x] [Cited by in Crossref: 137] [Cited by in F6Publishing: 143] [Article Influence: 27.4] [Reference Citation Analysis]
99 Gusscott S, Jenkins CE, Lam SH, Giambra V, Pollak M, Weng AP. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. PLoS One 2016;11:e0161158. [PMID: 27532210 DOI: 10.1371/journal.pone.0161158] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
100 Sharma J, Bhardwaj V, Purohit R. Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight. ACS Omega 2019;4:15815-23. [PMID: 31592171 DOI: 10.1021/acsomega.9b01439] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
101 Kaavya J, Mahalaxmi I, Devi SM, Santhy KS, Balachandar V. Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route? J Cell Physiol 2019;234:8259-73. [PMID: 30370571 DOI: 10.1002/jcp.27673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Hemmati S, Sinclair T, Tong M, Bartholdy B, Okabe RO, Ames K, Ostrodka L, Haque T, Kaur I, Mills TS, Agarwal A, Pietras EM, Zhao JJ, Roberts TM, Gritsman K. PI3 kinase alpha and delta promote hematopoietic stem cell activation. JCI Insight 2019;5:125832. [PMID: 31120863 DOI: 10.1172/jci.insight.125832] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
103 Jiang X, Chen S, Asara JM, Balk SP. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 2010;285:14980-9. [PMID: 20231295 DOI: 10.1074/jbc.M109.085696] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
104 Löf-Öhlin ZM, Nyeng P, Bechard ME, Hess K, Bankaitis E, Greiner TU, Ameri J, Wright CV, Semb H. EGFR signalling controls cellular fate and pancreatic organogenesis by regulating apicobasal polarity. Nat Cell Biol 2017;19:1313-25. [PMID: 29058721 DOI: 10.1038/ncb3628] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
105 Yamaguchi H, Yoshida S, Muroi E, Yoshida N, Kawamura M, Kouchi Z, Nakamura Y, Sakai R, Fukami K. Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation. J Cell Biol 2011;193:1275-88. [PMID: 21708979 DOI: 10.1083/jcb.201009126] [Cited by in F6Publishing: 84] [Reference Citation Analysis]
106 Rajala RV, Ranjo-Bishop M, Wang Y, Rajala A, Anderson RE. The p110α isoform of phosphoinositide 3-kinase is essential for cone photoreceptor survival. Biochimie 2015;112:35-40. [PMID: 25742742 DOI: 10.1016/j.biochi.2015.02.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
107 Derakhshandeh-Peykar P, Alivi J, Hossein-nezhad A, Rautenstrauss B, Vesal RE, Doriani A. High frequency of mutations in the PIK3CA gene helical and kinase coding regions in a group of Iranian patients with high-grade glioblastomas: five novel mutations. J Neurogenet 2011;25:189-94. [PMID: 22026810 DOI: 10.3109/01677063.2011.623202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
108 Schaffhausen BS, Roberts TM. Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer. Virology. 2009;384:304-316. [PMID: 19022468 DOI: 10.1016/j.virol.2008.09.042] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
109 Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM, Zhao JJ. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 2014;111:6395-400. [PMID: 24737887 DOI: 10.1073/pnas.1323004111] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
110 Bergholz JS, Roberts TM, Zhao JJ. Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. J Clin Oncol 2018;36:1339-42. [PMID: 29517943 DOI: 10.1200/JCO.2017.77.0891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
111 Matheny RW Jr, Riddle-Kottke MA, Leandry LA, Lynch CM, Abdalla MN, Geddis AV, Piper DR, Zhao JJ. Role of phosphoinositide 3-OH kinase p110β in skeletal myogenesis. Mol Cell Biol 2015;35:1182-96. [PMID: 25605332 DOI: 10.1128/MCB.00550-14] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
112 Dornan GL, Burke JE. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases. Front Immunol 2018;9:575. [PMID: 29616047 DOI: 10.3389/fimmu.2018.00575] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
113 Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, Paktinat M, Okabe RO, Roberts TM, Zhao JJ. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. J Clin Invest 2014;124:1794-809. [PMID: 24569456 DOI: 10.1172/JCI69927] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
114 Soler A, Serra H, Pearce W, Angulo A, Guillermet-Guibert J, Friedman LS, Viñals F, Gerhardt H, Casanovas O, Graupera M, Vanhaesebroeck B. Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J Exp Med 2013;210:1937-45. [PMID: 24043760 DOI: 10.1084/jem.20121571] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
115 Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009;69:3955-3962. [PMID: 19366795 DOI: 10.1158/0008-5472.CAN-08-4450] [Cited by in Crossref: 161] [Cited by in F6Publishing: 78] [Article Influence: 12.4] [Reference Citation Analysis]
116 Dou Z, Chattopadhyay M, Pan JA, Guerriero JL, Jiang YP, Ballou LM, Yue Z, Lin RZ, Zong WX. The class IA phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy. J Cell Biol 2010;191:827-43. [PMID: 21059846 DOI: 10.1083/jcb.201006056] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
117 Schoenwaelder SM, Ono A, Sturgeon S, Chan SM, Mangin P, Maxwell MJ, Turnbull S, Mulchandani M, Anderson K, Kauffenstein G, Rewcastle GW, Kendall J, Gachet C, Salem HH, Jackson SP. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha IIb beta 3 adhesive function in platelets. J Biol Chem 2007;282:28648-58. [PMID: 17673465 DOI: 10.1074/jbc.M704358200] [Cited by in Crossref: 69] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
118 Maira S, Voliva C, Garcia-echeverria C. Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opinion on Therapeutic Targets 2008;12:223-38. [DOI: 10.1517/14728222.12.2.223] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
119 Sopasakis VR, Liu P, Suzuki R, Kondo T, Winnay J, Tran TT, Asano T, Smyth G, Sajan MP, Farese RV, Kahn CR, Zhao JJ. Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metab 2010;11:220-30. [PMID: 20197055 DOI: 10.1016/j.cmet.2010.02.002] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 7.1] [Reference Citation Analysis]
120 Bobrovnikova-Marjon E, Pytel D, Riese MJ, Vaites LP, Singh N, Koretzky GA, Witze ES, Diehl JA. PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation. Mol Cell Biol 2012;32:2268-78. [PMID: 22493067 DOI: 10.1128/MCB.00063-12] [Cited by in Crossref: 72] [Cited by in F6Publishing: 50] [Article Influence: 7.2] [Reference Citation Analysis]
121 Robertson DG, Datta K, Wells D, Egnash L, Robosky L, Manning M, Rohde C, Reily MD. Metabonomic Evaluation of Metabolic Dysregulation in Rats Induced by PF 376304, a Novel Inhibitor of Phosphoinositide 3-Kinase. Chem Res Toxicol 2007;20:1871-7. [DOI: 10.1021/tx7002036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
122 Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One. 2010;5:e9646. [PMID: 20333297 DOI: 10.1371/journal.pone.0009646] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 7.5] [Reference Citation Analysis]
123 Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, Lee C, Haywood S, Chen X, Chang Q, Xu G, Chen HA, de Stanchina E, Sawyers C, Rosen N, Hsieh AC, Chen Y, Carver BS. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nat Commun 2021;12:5053. [PMID: 34417459 DOI: 10.1038/s41467-021-25341-9] [Reference Citation Analysis]
124 Borges BC, Garcia-Galiano D, Rorato R, Elias LLK, Elias CF. PI3K p110β subunit in leptin receptor expressing cells is required for the acute hypophagia induced by endotoxemia. Mol Metab 2016;5:379-91. [PMID: 27257598 DOI: 10.1016/j.molmet.2016.03.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
125 Zhang C, Xu B, Liu P. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. Tumour Biol 2016;37:14831-9. [PMID: 27639383 DOI: 10.1007/s13277-016-5381-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
126 Castellano E, Downward J. Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol. 2010;346:143-169. [PMID: 20563706 DOI: 10.1007/82_2010_56] [Cited by in Crossref: 21] [Cited by in F6Publishing: 60] [Article Influence: 1.9] [Reference Citation Analysis]
127 Xie S, Ni J, McFaline-Figueroa JR, Wang Y, Bronson RT, Ligon KL, Wen PY, Roberts TM, Zhao JJ. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep 2020;32:108196. [PMID: 32997991 DOI: 10.1016/j.celrep.2020.108196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
128 Liang S, Yang N, Pan Y, Deng S, Lin X, Yang X, Katsaros D, Roby KF, Hamilton TC, Connolly DC, Coukos G, Zhang L. Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PLoS One 2009;4:e4295. [PMID: 19172191 DOI: 10.1371/journal.pone.0004295] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
129 Mclean BA, Zhabyeyev P, Pituskin E, Paterson I, Haykowsky MJ, Oudit GY. PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine. Journal of Cardiac Failure 2013;19:268-82. [DOI: 10.1016/j.cardfail.2013.02.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
130 Matheny RW Jr, Lynch CM, Leandry LA. Enhanced Akt phosphorylation and myogenic differentiation in PI3K p110β-deficient myoblasts is mediated by PI3K p110α and mTORC2. Growth Factors 2012;30:367-84. [PMID: 23137199 DOI: 10.3109/08977194.2012.734507] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
131 Miller MS, Maheshwari S, McRobb FM, Kinzler KW, Amzel LM, Vogelstein B, Gabelli SB. Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design. Bioorg Med Chem 2017;25:1481-6. [PMID: 28129991 DOI: 10.1016/j.bmc.2017.01.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
132 Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, Moore C, Kumar MS, Murillo MM, Grönroos E, Lassailly F, Stamp G, Downward J. Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 2013;24:617-30. [PMID: 24229709 DOI: 10.1016/j.ccr.2013.09.012] [Cited by in Crossref: 117] [Cited by in F6Publishing: 112] [Article Influence: 14.6] [Reference Citation Analysis]
133 Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One. 2012;7:e44146. [PMID: 22952903 DOI: 10.1371/journal.pone.0044146] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
134 Zhang J, Gao X, Schmit F, Adelmant G, Eck MJ, Marto JA, Zhao JJ, Roberts TM. CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep 2017;20:549-57. [PMID: 28723560 DOI: 10.1016/j.celrep.2017.06.054] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
135 Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology. 2011;141:50-61. [PMID: 21723986 DOI: 10.1053/j.gastro.2011.05.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
136 Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 2010;107:11381-6. [PMID: 20534549 DOI: 10.1073/pnas.0906461107] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 9.4] [Reference Citation Analysis]
137 Liu H, Mi S, Li Z, Hua F, Hu ZW. Interleukin 17A inhibits autophagy through activation of PIK3CA to interrupt the GSK3B-mediated degradation of BCL2 in lung epithelial cells. Autophagy 2013;9:730-42. [PMID: 23514933 DOI: 10.4161/auto.24039] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.8] [Reference Citation Analysis]
138 Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007;129:957-968. [PMID: 17540175 DOI: 10.1016/j.cell.2007.03.051] [Cited by in Crossref: 426] [Cited by in F6Publishing: 397] [Article Influence: 28.4] [Reference Citation Analysis]
139 Chaudhari A, Ejeskär K, Wettergren Y, Kahn CR, Rotter Sopasakis V. Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity. F1000Res 2017;6:1600. [PMID: 29983910 DOI: 10.12688/f1000research.12418.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
140 Hill KM, Kalifa S, Das JR, Bhatti T, Gay M, Williams D, Taliferro-Smith L, De Marzo AM. The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells. Prostate 2010;70:755-64. [PMID: 20058239 DOI: 10.1002/pros.21108] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
141 Kim MJ, Lee SJ, Ryu JH, Kim SH, Kwon IC, Roberts TM. Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment. J Control Release 2020;318:98-108. [PMID: 31838203 DOI: 10.1016/j.jconrel.2019.12.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
142 Krygowska AA, Castellano E. PI3K: A Crucial Piece in the RAS Signaling Puzzle. Cold Spring Harb Perspect Med 2018;8:a031450. [PMID: 28847905 DOI: 10.1101/cshperspect.a031450] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
143 Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P. Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases. Prog Med Chem 2009;48:81-131. [PMID: 21544958 DOI: 10.1016/s0079-6468(09)04803-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
144 Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7-24. [PMID: 25533673 DOI: 10.1038/nrc3860] [Cited by in Crossref: 709] [Cited by in F6Publishing: 657] [Article Influence: 101.3] [Reference Citation Analysis]
145 Wang Q, Weisberg E, Zhao JJ. The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome. Cell Cycle 2013;12:3589-93. [PMID: 24131925 DOI: 10.4161/cc.26812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
146 Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, Diefenbacher M, Stamp G, Downward J. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 2013;153:1050-63. [PMID: 23706742 DOI: 10.1016/j.cell.2013.04.031] [Cited by in Crossref: 184] [Cited by in F6Publishing: 172] [Article Influence: 20.4] [Reference Citation Analysis]
147 Engelbrecht AM, Mattheyse M, Ellis B, Loos B, Thomas M, Smith R, Peters S, Smith C, Myburgh K. Proanthocyanidin from grape seeds inactivates the PI3-kinase/PKB pathway and induces apoptosis in a colon cancer cell line. Cancer Lett. 2007;258:144-153. [PMID: 17923279 DOI: 10.1016/j.canlet.2007.08.020] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 5.4] [Reference Citation Analysis]
148 Neupane M, Clark AP, Landini S, Birkbak NJ, Eklund AC, Lim E, Culhane AC, Barry WT, Schumacher SE, Beroukhim R, Szallasi Z, Vidal M, Hill DE, Silver DP. MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. Cancer Discov 2016;6:45-58. [PMID: 26546296 DOI: 10.1158/2159-8290.CD-15-0341] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
149 Huang Y, He Z, Gao Y, Lieu L, Yao T, Sun J, Liu T, Javadi C, Box M, Afrin S, Guo H, Williams KW. Phosphoinositide 3-Kinase Is Integral for the Acute Activity of Leptin and Insulin in Male Arcuate NPY/AgRP Neurons. J Endocr Soc 2018;2:518-32. [PMID: 29850651 DOI: 10.1210/js.2018-00061] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
150 Ghosh S, Lau H, Simons BW, Powell JD, Meyers DJ, De Marzo AM, Berman DM, Lotan TL. PI3K/mTOR signaling regulates prostatic branching morphogenesis. Dev Biol 2011;360:329-42. [PMID: 22015718 DOI: 10.1016/j.ydbio.2011.09.027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
151 Del Re M, Crucitta S, Lorenzini G, De Angelis C, Diodati L, Cavallero D, Bargagna I, Cinacchi P, Fratini B, Salvadori B, Ghilli M, Roncella M, Fontana A, Danesi R, Cucchiara F. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. Pharmacol Res 2021;163:105241. [PMID: 33049397 DOI: 10.1016/j.phrs.2020.105241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
152 Stamatkin C, Ratermann KL, Overley CW, Black EP. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. Cancer Biol Ther 2015;16:1341-52. [PMID: 26176612 DOI: 10.1080/15384047.2015.1070986] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
153 Fitter S, Vandyke K, Gronthos S, Zannettino AC. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol 2012;48:229-40. [PMID: 22474082 DOI: 10.1530/JME-12-0003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
154 Zwang NA, Zhang R, Germana S, Fan MY, Hastings WD, Cao A, Turka LA. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Am J Transplant 2016;16:2624-38. [PMID: 27017850 DOI: 10.1111/ajt.13805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
155 Sun YY, Bai WW, Wang B, Lu XT, Xing YF, Cheng W, Liu XQ, Zhao YX. Period 2 is essential to maintain early endothelial progenitor cell function in vitro and angiogenesis after myocardial infarction in mice. J Cell Mol Med 2014;18:907-18. [PMID: 24621388 DOI: 10.1111/jcmm.12241] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]